Christina Therkildsen

Research group leader

Copenhagen University Hospital
Country flagDenmark
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (4)

Supplementary Table S1. Summary of clinical information. Supplementary Table S2. Summary of sample characteristics. Supplementary Table S3. Summary of whole-genome sequencing and fragment analyses. Supplementary Table S4. Summary of protein analyses. Supplementary Table S5. Summary of machine learning models and scores. Supplementary Table S6. Summary of performance for ovarian cancer detection.

Year:

2025

Ovarian cancer is a leading cause of death for women worldwide, in part due to ineffective screening methods. In this study, we used whole-genome cell-free DNA (cfDNA) fragmentome and protein biomarker [cancer antigen 125 (CA-125) and human epididymis protein 4 (HE4)] analyses to evaluate 591 women with ovarian cancer, with benign adnexal masses, or without ovarian lesions. Using a machine learning model with the combined features, we detected ovarian cancer with specificity >99% and sensitivities of 72%, 69%, 87%, and 100% for stages I to IV, respectively. At the same specificity, CA-125 alone detected 34%, 62%, 63%, and 100%, and HE4 alone detected 28%, 27%, 67%, and 100% of ovarian cancers for stages I to IV, respectively. Our approach differentiated benign masses from ovarian cancers with high accuracy (AUC = 0.88, 95% confidence interval, 0.83–0.92). These results were validated in an independent population. These findings show that integrated cfDNA fragmentome and protein analyses detect ovarian cancers with high performance, enabling a new accessible approach for noninvasive ovarian cancer screening and diagnostic evaluation. Significance: There is an unmet need for effective ovarian cancer screening and diagnostic approaches that enable earlier-stage cancer detection and increased overall survival. We have developed a high-performing accessible approach that evaluates cfDNA fragmentomes and protein biomarkers to detect ovarian cancer.

Year:

2025

Supplementary Figure S1. Evaluation of screening model DELFI-Pro scores and comorbidities in individuals without cancer. Supplementary Figure S2. DELFI-Pro score evaluation in available clinical characteristics of patients with cancer. Supplementary Figure S3. Stability analysis across fold repeats and collection source. Supplementary Figure S4. Detection of ovarian cancer subtypes using DELFI-Pro screening model. Supplementary Figure S5. ROC analyses of asymptomatic individuals in the using screening or diagnostic models in the Discovery Cohort. Supplementary Figure S6. Performance of ichorCNA and median cfDNA fragment lengths in the Discovery Cohorts. Supplementary Figure S7. Detection of ovarian cancer subtypes using DELFI-Pro at high specificity. Supplementary Figure S8. Genome-wide fragmentation profiles are altered in patients in the Validation Cohort with ovarian cancer. Supplementary Figure S9. Analyses of chromosomal changes in Discovery and Validation cohorts. Supplementary Figure S10. Performance of DELFI-Pro for detection of ovarian cancer in the Validation Cohort. Supplementary Figure S11. Correlation of rank ordered DELFI-Pro scores for the Screening and Diagnostic models. Supplementary Figure S12. Assessment of DELFI-Pro in women with benign lesions. Supplementary Figure S13. Performance of DELFI-Pro for distinguishing ovarian cancer from benign masses. Supplementary Figure S14. Performance of DELFI-Pro for distinguishing ovarian cancer subtypes from benign masses. Supplementary Figure S15. Performance of DELFI-Pro for distinguishing ovarian cancer subtypes from benign masses in Validation Cohort. Supplementary Figure S16. Evaluation of overall tumor burden using the sum of reported lesion diameters. Supplementary Figure S17. Evaluation of CA1-25 and HE4 blood concentrations measured at different centers.

Year:

2025

The fragmentation patterns of whole genome sequenced cell-free DNA are promising features for tumor-agnostic cancer detection. However, systematic biases challenge their cross-cohort generalization. We introduce LIONHEART, a novel, open source cancer detection method specifically optimized to generalize across datasets. The method correlates bias-corrected cfDNA fragment coverage across the genome with the locations of accessible chromatin regions from 898 cell and tissue type features. We use these correlations to detect changes in the cell-free DNA cell type composition caused by cancer. We test LIONHEART on nine datasets and fourteen cancer types (1106 non-cancer controls, 1449 cancers) obtained from different studies and show that it can distinguish cancer samples from non-cancer controls across cohorts with ROC AUC scores ranging from 0.62-0.95 (mean = 0.83, std = 0.12). We further validate the method on an external dataset, achieving a ROC AUC of 0.917.

Year:

2024

Collaborators (22)

Mads Ryø Jochumsen

Aarhus University

DENMARK
View details

Jillian Phallen

Johns Hopkins University School of Medicine

UNITED STATES
View details

Tenna Henriksen

VIP, Tenure Track Assistant Professor

Aarhus University

DENMARK
View details

Susan Domchek

Professor, Clinician-Educator

University of Pennsylvania

UNITED STATES
View details

Gerrit Meijer

Professor of Oncologic Pathology

University Medical Center Groningen

NETHERLANDS
View details

Dimitrios Mathios

Assistant Professor

Washington University in St. Louis

UNITED STATES
View details

Victor E. Velculescu

Assistant/Associate/Professor of Oncology and Pathology

Johns Hopkins University School of Medicine

UNITED STATES
View details

Marijana Nesic

Aarhus University Hospital

DENMARK
View details

Lars Dyrskjøt

Aarhus University Hospital

DENMARK
View details

Anders Jacobsen Skanderup

Principal Investigator

Genome Institute of Singapore

SINGAPORE
View details

Amanda Frydendahl

Aarhus University

DENMARK
View details

Karina Dalsgaard Sørensen

VIP, Professor

Aarhus University

DENMARK
View details

Dennis J. Slamon

University of California, Los Angeles

UNITED STATES
View details

Michael Borre

Chair professor

Aarhus University Hospital

DENMARK
View details

Jenna Canzoniero

Assistant Professor - Women's Malignancies Program

Johns Hopkins University School of Medicine

UNITED STATES
View details

Claus Lindbjerg Andersen

VIP, Professor

Aarhus University

DENMARK
View details

Beatriz Carvalho

Senior scientist

The Netherlands Cancer Institute

NETHERLANDS
View details

Iver Kristiansen Nordentoft

Senior Researcher

Aarhus Universitetshospital

DENMARK
View details

Ronny Drapkin

Franklin Payne Professor of Pathology in Obstetrics and Gynecology

University of Pennsylvania

UNITED STATES
View details

Søren Besenbacher

Associate Professor

Aarhus University

DENMARK
View details

Robert B Scharpf

Associate Professor

Johns Hopkins University School of Medicine

UNITED STATES
View details

Mads Heilskov Rasmussen

VIP, Associate Professor

Aarhus University

DENMARK
View details